Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes
DOI:
https://doi.org/10.15277/bjd.2018.180Keywords:
diabetes, lipids, fibrates, niacin, PCSK9 inhibitorsAbstract
Statin therapy is proven to reduce cardiovascular morbidity and mortality in people with diabetes, and high-dose statins are recommended for people with established atherosclerotic vascular disease. In two dedicated studies in people with diabetes, fibrates did not significantly reduce cardiovascular events and were associated with serious side effects. A similar lack of benefit was seen in two large studies of niacin. Ezetimibe, when added to statins, may further reduce LDL cholesterol and non-fatal vascular events. The PCSK9 inhibitors are a new class of subcutaneous lipid- lowering drugs which cause profound reductions in LDL cholesterol when added to statins. Evolocumab reduced non-fatal cardiovascular events when added to background statin therapy in a larger group of subjects and the benefits were confirmed in a diabetes subgroup. In another large trial alirocumab reduced major adverse cardiovascular events and total mortality. The clinical use of ezetimibe and PCSK9 inhibitors is currently limited by cost.
References
Naeem F, McKay G, Fisher M. Cardiovascular outcomes trials with statins in diabetes. Br J Diabetes 2018;18:7–13. https://doi.org/10.15277/bjd.2018.161
Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–93. https://doi.org/10.1161/01.CIR.98.19.2088
Keech A, Simes RJ, Barter B, et al, on behalf of the FIELD Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes (the FIELD study): a randomised controlled trial. Lancet 2005;366:1849–61. https://doi.org/10.1016/S0140-6736(05)67667-2
Scott R, O’Brien R, Fulcher G, et al, on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 2009;32:493–8. https://doi.org/10.2337/dc08-1543
Action to Control Cardiovascular Disease in Diabetes Study Group. Effects of intensive blood glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59. https://doi.org/10.1056/NEJMoa0802743.
ACCORD Study Group. Effects on intensive blood-pressure control in diabetes. N Engl J Med 2010;362:1575–85. https://doi.org/10.1056/NEJMoa1001286
ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes. N Engl J Med 2010;362:1563–74. https://doi.org/10.1056/NEJMoa1001282
AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving statin therapy. N Engl J Med 2011;365:2255–67. https://doi.org/10.1056/NEJMoa1107579
Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008;83:470–8. https://doi.org/10.4065/83.4.470
HPS-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203–12. https://doi.org/10.1056/NEJMoa1300955
Sattar N, Preiss D, Murray HM, et al. Satins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–42. https://doi.org/10.1016/S0140-6736(09)61965-6.
Cannon CP, Blazing MA, Giugliano RP, et al, for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute cornary synromes. N Engl J Med 2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489
Giugliano RP, Cannon CP, Blazing MA, et al, on behalf of the IMPROVE-IT Investigators. Benefit of adding ezetimibe to a statin on cardiovascular outcomes and safety in patients with vs. without diabetes: results form IMPROVE-IT. Circulation 2017 Dec 20. https://doi.org/10.1161/CIRCULATIONAHA.117.030950.
Mark PB, Winocour P, Day C. Management of lipids in adults with diabetes mellitus and nephropathy and/or chronic kidey disease: summary of joint guidance from the ABCD and the RA. Br J Diabetes 2017;17:64–72. https://doi.org/10.15277/bjd.2017.125
Baigent C, Landray MJ, Reith C, et al, on behalf of the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised-placebo controlled trial. Lancet 2011;377:2181–92. https://doi.org/10.1016/S0140-6736(11)60739-3
Barter PJ, Caulfield M, Eriksson M, et al, for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk of coronary events. N Engl J Med 2007;357:2109–22. https://doi.org/10.1056/NEJMoa0706628
Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increasing circulating levels of aldosterone. Br J Pharmacol 2008;154:1465–73. https://doi.org/10.1038/bjp.2008.229
Barter PJ, Rye K-A, Tardif J-C, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 2011;124:555–62. https://doi.org/10.1161/CIRCULATIONAHA.111.018259
Schwartz GC, Olsson AG, Abt M, et al, for the dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089–99. https://doi.org/10.1056/NEJMoa1206797
Lincoff AM, Nicholls SJ, Reismyer JS, et al, for the ACCELERATE Investigators. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 2017;376:1933–42. https://doi.org/10.1056/NEJMoa1609581
HPS3/TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017;377:1217–27. https://doi.org/10.1056/NEJMoa1706444
Sabatine MS, Giugliano RP, Keech AC, et al, for the FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664
Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 2017;5:941–50. 10.1016/S2213-8587(17)30313-3
Robinson JG, Farnier M, Krempf M, et al, for the ODYSSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489–99. https://doi.org/10.1056/NEJMoa1501031
Schwartz GC, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial. Am Heart J 2014;168:682–9. https://doi.org/10.1016/j.ahj.2014.07.028
Jarcho JA, Keaney JF. Proof that lower is better – LDL cholesterol and IMPROVE-IT. N Engl J Med 2015;372:2448–50. https://doi.org/10.1056/NEJMe1507041
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
